JP2023521030A5 - - Google Patents
Info
- Publication number
- JP2023521030A5 JP2023521030A5 JP2022560218A JP2022560218A JP2023521030A5 JP 2023521030 A5 JP2023521030 A5 JP 2023521030A5 JP 2022560218 A JP2022560218 A JP 2022560218A JP 2022560218 A JP2022560218 A JP 2022560218A JP 2023521030 A5 JP2023521030 A5 JP 2023521030A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- ibudilast
- pharmaceutically acceptable
- acceptable salt
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005792P | 2020-04-06 | 2020-04-06 | |
| US63/005,792 | 2020-04-06 | ||
| PCT/US2021/025732 WO2021207054A1 (en) | 2020-04-06 | 2021-04-05 | Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521030A JP2023521030A (ja) | 2023-05-23 |
| JP2023521030A5 true JP2023521030A5 (cg-RX-API-DMAC7.html) | 2024-04-15 |
Family
ID=75674991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560218A Pending JP2023521030A (ja) | 2020-04-06 | 2021-04-05 | イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12213966B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4132521A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023521030A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115335049A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174413A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021207054A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2745814C1 (ru) * | 2020-06-05 | 2021-04-01 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция левилимаба и ее применение |
| JP2024528731A (ja) | 2021-07-26 | 2024-07-30 | メディシノバ・インコーポレイテッド | 眼癌転移を予防するためのイブジラスト |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
| JP2025504984A (ja) | 2022-02-01 | 2025-02-19 | メディシノバ・インコーポレイテッド | Covid後症状の治療における使用のためのイブジラスト |
| US20240016729A1 (en) * | 2022-07-13 | 2024-01-18 | Medicinova, Inc. | Injectable formulations of ibudilast |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8562198A (en) | 1998-08-10 | 2000-03-06 | Kyorin Pharmaceutical Co. Ltd. | Remedies for multiple sclerosis |
| JP2007512337A (ja) * | 2003-11-21 | 2007-05-17 | コンビナトアールエックス インコーポレーティッド | 炎症性障害の治療のための方法および試薬 |
| WO2006063048A2 (en) | 2004-12-06 | 2006-06-15 | Avigen, Inc. | Ibudilast for treating neuropathic pain and associated syndromes |
| EP2026804A1 (en) * | 2006-05-31 | 2009-02-25 | Avigen, Inc. | Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity |
| CA2693697C (en) * | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| US20110028510A1 (en) * | 2009-02-18 | 2011-02-03 | Combinatorx (Singapore) Pte. Ltd. | Compositions, Methods, and Kits for Treating Influenza Viral Infections |
| EP3558301A4 (en) * | 2016-12-22 | 2020-07-29 | MediciNova, Inc. | METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST |
| CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
| CA3090887A1 (en) * | 2018-02-12 | 2019-08-15 | Medicinova, Inc. | Methods of suppressing myeloid-derived suppressor cells in patients |
-
2021
- 2021-04-05 CN CN202180024762.3A patent/CN115335049A/zh active Pending
- 2021-04-05 WO PCT/US2021/025732 patent/WO2021207054A1/en not_active Ceased
- 2021-04-05 US US17/222,673 patent/US12213966B2/en active Active
- 2021-04-05 EP EP21721728.0A patent/EP4132521A1/en active Pending
- 2021-04-05 CA CA3174413A patent/CA3174413A1/en active Pending
- 2021-04-05 JP JP2022560218A patent/JP2023521030A/ja active Pending
-
2025
- 2025-01-10 US US19/016,999 patent/US20250221969A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020033360A5 (cg-RX-API-DMAC7.html) | ||
| JP2014515373A5 (cg-RX-API-DMAC7.html) | ||
| US20230364044A1 (en) | Methods of Treating or Preventing Acute Respiratory Distress Syndrome | |
| BR112012015202B1 (pt) | uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica | |
| ES2906551T3 (es) | Uso de hidrocloruro de landiolol en el tratamiento a largo plazo de taquiarritmias | |
| CN1379665A (zh) | 通过吸入法送递联苯胺前列腺素的方法 | |
| JP2023523557A5 (cg-RX-API-DMAC7.html) | ||
| US12514830B2 (en) | Idebenone for the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients diagnosed with a coronavirus infection | |
| JP2024540439A5 (cg-RX-API-DMAC7.html) | ||
| JP2024531799A5 (cg-RX-API-DMAC7.html) | ||
| JP2022177119A5 (cg-RX-API-DMAC7.html) | ||
| EP4142731A1 (en) | Treatment of pulmonary complications of coronavirus infections | |
| MX2012005551A (es) | Tratamiento de infecciones microbianas. | |
| ES2894330T3 (es) | Acido acetilsalicílico para uso en el tratamiento de la influenza de moderada a grave | |
| CN113694177B (zh) | 器官损伤的预防和治疗 | |
| US20230346793A1 (en) | Compositions and Methods for Treating SARS-CoV-2 | |
| RU2018144248A (ru) | Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта | |
| JP2013523844A5 (cg-RX-API-DMAC7.html) | ||
| WO2021207489A1 (en) | Methods and pharmaceutical compositions to treat pulmonary inflammation in infected patients | |
| JP2023518430A5 (cg-RX-API-DMAC7.html) | ||
| JP2022542305A5 (cg-RX-API-DMAC7.html) | ||
| RU2830584C1 (ru) | Ингибиторы cxcl8 для применения в лечении covid-19 | |
| JP2019533018A5 (cg-RX-API-DMAC7.html) | ||
| EP4008325A1 (en) | Cxcl8 inhibitors for use in the treatment of covid-19 | |
| US20230141355A1 (en) | Cxcl8 inhibitors for use in the treatment of covid-19 |